Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT05079230

Public ClinicalTrials.gov record NCT05079230. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical study is to compare the study drugs, magrolimab + venetoclax + azacitidine, versus placebo + venetoclax + azacitidine in participants with untreated acute myeloid leukemia (AML) who are not able to have chemotherapy.

Study identification

NCT ID
NCT05079230
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Gilead Sciences
Industry
Enrollment
378 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 6, 2022
Primary completion
Apr 10, 2024
Completion
Apr 10, 2024
Last update posted
Apr 3, 2025

2022 – 2024

United States locations

U.S. sites
39
U.S. states
21
U.S. cities
34
Facility City State ZIP Site status
University of Arkansas for Medical Sciences Little Rock Arkansas 72205
City of Hope (City of Hope National Medical Center, City of Hope Medical Center) Duarte California 91010
Community Cancer Institute Fresno California 93730
UC Irvine Health- Chao Family Comprehensive Cancer Center Orange California 92868
Baptist MD Anderson Cancer Center Jacksonville Florida 32207
Moffitt Cancer Center Tampa Florida 33612
Loyola University Medical Center Maywood Illinois 60153
Parkview Research Center Fort Wayne Indiana 46845
Indiana Blood and Marrow Transplantation - Clinic Indianapolis Indiana 46237
The University of Iowa Hospitals and Clinics Iowa City Iowa 52242
University of Maryland, Greenebaum Comprehensive Cancer Center Baltimore Maryland 21201
University of Massachusetts Worcester Worcester Massachusetts 01655
MidAmerica Division, Inc., c/o Research Medical Center Kansas City Missouri 64132
SSM Health Saint Louis University Hospital St Louis Missouri 63110
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901
New York-Presbyterian/Weill Cornell Medical Center New York New York 10021
Icahn School of Medicine at Mount Sinai and The Mount Sinai Hospital New York New York 10029
University of Rochester Medical Center Rochester New York 14642
UNC Hospitals, The University of North Carolina at Chapel Hill Chapel Hill North Carolina 27514
Novant Health Cancer Institute Hematology- Charlotte Charlotte North Carolina 28204
Novant Health Cancer Institute Hematology - Forsyth Winston-Salem North Carolina 27103
Wake Forest Baptist Health Winston-Salem North Carolina 27103
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
Cleveland Clinic Foundation Cleveland Ohio 44195
OU Health Stephenson Cancer Center Oklahoma City Oklahoma 73104
Providence Cancer Institute Franz Clinic Portland Oregon 97213
Penn State Hershey Medical Center Hershey Pennsylvania 17033
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
West Penn Hospital Pittsburgh Pennsylvania 15224
Rhode Island Hospital Providence Rhode Island 02903
Baylor University Medical Center Dallas Texas 75246
Brooke Army Medical Center Fort Sam Houston Texas 78234
Houston Methodist Hospital Cancer Center Houston Texas 77030
MD Anderson Cancer Center Houston Texas 77030
Intermountain Health - LDS Hospital Salt Lake City Utah 84143
Virginia Mason Franciscan Health Seattle Washington 98101
Fred Hutchinson Cancer Center Seattle Washington 98109
Froedtert Hospital and the Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 125 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05079230, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05079230 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →